Surgalign Announces Partnership with PRIA Healthcare to Improve Patient Healthcare Coverage
July 14 2022 - 8:30AM
Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical
technology company focused on elevating the standard of care by
driving the evolution of digital health, announced PRIA Healthcare
will serve as a strategic partner in support of the recently
launched Surgalign™ Patient Access Program.
The objective of the Surgalign Patient Access Program is to help
patients realize improved access to medical technologies that drive
better outcomes, such as the Company’s Coflex Interlaminar
Stabilization and SImmetry Sacroiliac (SI) Joint Fusion systems. As
a relentless advocate for patients, PRIA brings to the
collaboration more than 10 years of experience partnering with
MedTech companies to improve patient access to the latest medical
technologies.
Terry Rich, President and Chief Executive Officer of Surgalign
stated, “Our vision at Surgalign is to drive optimal patient
outcomes while advancing the standard of spine care. We partnered
with PRIA because of their extensive experience advocating for
patients to receive favorable medical coverage. Ultimately this
program will expand patient access to procedures and devices such
as the Coflex Interlaminar Stabilization and SImmetry SI Joint
Fusion systems.”
The Coflex Interlaminar Stabilization device is a lumbar motion
preservation solution that maintains stability in the spine after
direct surgical decompression while preserving more natural
movement. Coflex has Level 1 clinical data from a randomized
control trial used for PMA approval that has been reported in the
International Journal of Spine Surgery1. Further, the Coflex
device appears in more than 90 peer reviewed publications and
has been implanted more than 175,000 times globally.
The SImmetry SI Joint Fusion system is the only lateral approach
SI procedure that follows orthopedic principles of joint
decortication, bone grafting and fixation, to create the best
possible environment to achieve true arthrodesis. The recently
published SImmetry EVoluSIon study (EVSI), one of the largest SI
joint fusion studies conducted to date, showed statistically
significant improvements in both pain and disability, along with a
statistically significant reduction in the number of patients using
opioids at 12 months2.
“We look forward to seeing the positive impact PRIA’s
streamlined authorization and appeal process has on the challenges
patients face to obtain medical coverage for needed care,” added
Scott Durall, Chief Commercial Officer of Surgalign. “This
partnership highlights our commitment to supporting our physician
and patient community by educating payers on the clinical benefits
of novel therapies such as Coflex and SImmetry, that provide
positive clinical outcomes for patients.”
1 Musacchio MJ, Lauryssen C, Davis RJ, et al.
Evaluation of Decompression and Interlaminar Stabilization Compared
with Decompression and Fusion for the Treatment of Lumbar Spinal
Stenosis: 5-year Follow-up of a Prospective, Randomized, Controlled
Trial. Int. J. Spine Surg. 2016 Jan 26;10:6. Doi: 10.14444/3006.
eCollection 2016. 2 Kucharzyk D, Colle K, Boone C, Araghi A.
Clinical outcomes following minimally invasive sacroiliac joint
fusion with decortication: The EVoluSIon clinical study. Int. J.
Spine Surg. 2022, 16 (1) 168-175. doi:
https://doi.org/10.14444/8185.
About Surgalign Holdings, Inc.Surgalign
Holdings, Inc. is a global medical technology company committed to
the promise of digital health to drive transformation across the
surgical landscape. Uniquely aligned and resourced to advance the
standard of care, the company is building technologies physicians
and other health providers will look to for what is truly possible
for their patients. Surgalign is focused on developing solutions
that predictably deliver superior clinical and economic outcomes.
Surgalign markets products throughout the United States and in more
than 50 countries worldwide through an expanding network of top
independent distributors. Surgalign is headquartered in Deerfield,
IL, with commercial, innovation and design centers in San Diego,
CA, Warsaw and Poznan, Poland, and Wurmlingen, Germany. Learn more
at http://www.surgalign.com and connect on LinkedIn and
Twitter.
About PRIA HealthcareSince 2012, PRIA
Healthcare has been a national leader in reimbursement and market
access to the healthcare arena throughout the United States. Led by
a team of industry veterans, PRIA is committed to ensuring the
latest medical technologies and procedures are available to
patients both during clinical trials and through product
commercialization. PRIA diligently works to influence payers to
establish patient access to life changing devices, therapies,
treatments, and procedures by leveraging clinical data, patient,
and physician rights.
Forward Looking StatementThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements are based on management’s current
expectations, estimates and projections about our products,
company, and industry, our management's beliefs, and certain
assumptions made by our management. Words such as "anticipates,"
"expects," "intends," "plans," "believes," "seeks," "estimates,"
and other variations of such words and similar expressions are
intended to identify such forward-looking statements. These
statements are not guarantees of future performance and are subject
to risks and uncertainties, including the risks described in our
public filings with the U.S. Securities and Exchange Commission
(SEC). Our actual results may differ materially from the
anticipated results reflected in these forward-looking statements.
Copies of the company's SEC filings may be obtained by contacting
the company or the SEC or by visiting Surgalign's website
at www.surgalign.com or the SEC's website
at www.sec.gov.
Investor and Media Contact: Glenn
Wienergwiener@gwcco.com + 1 917 887 8434 |
Surgalign Contact:Kristine
Simmonsksimmons@surgalign.com+1 619 206 4648 |
Surgalign (NASDAQ:SRGA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Surgalign (NASDAQ:SRGA)
Historical Stock Chart
From Apr 2023 to Apr 2024